Francesca Cardarelli, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Kidney Transplantation | 19 | 2024 | 4234 | 1.880 |
Why?
|
Polyomavirus Infections | 3 | 2024 | 194 | 0.950 |
Why?
|
Glomerulonephritis, IGA | 2 | 2019 | 63 | 0.790 |
Why?
|
Tumor Virus Infections | 3 | 2024 | 438 | 0.760 |
Why?
|
Graft Rejection | 9 | 2024 | 4445 | 0.660 |
Why?
|
BK Virus | 4 | 2024 | 123 | 0.660 |
Why?
|
Delayed Graft Function | 1 | 2019 | 53 | 0.660 |
Why?
|
Thigh | 1 | 2019 | 241 | 0.610 |
Why?
|
Arteriovenous Shunt, Surgical | 2 | 2019 | 292 | 0.610 |
Why?
|
HLA-DQ Antigens | 1 | 2018 | 191 | 0.590 |
Why?
|
Histocompatibility Testing | 1 | 2018 | 712 | 0.530 |
Why?
|
Renal Dialysis | 4 | 2019 | 1797 | 0.440 |
Why?
|
Angioplasty, Balloon, Coronary | 2 | 2009 | 1725 | 0.380 |
Why?
|
Kidney Failure, Chronic | 5 | 2018 | 2471 | 0.330 |
Why?
|
HLA Antigens | 2 | 2005 | 1328 | 0.330 |
Why?
|
Graft Survival | 6 | 2024 | 3819 | 0.310 |
Why?
|
Isoantibodies | 2 | 2006 | 674 | 0.240 |
Why?
|
Multiple Myeloma | 2 | 2021 | 5146 | 0.230 |
Why?
|
Creatinine | 2 | 2009 | 1899 | 0.220 |
Why?
|
Antilymphocyte Serum | 2 | 2024 | 487 | 0.220 |
Why?
|
Postoperative Complications | 3 | 2020 | 15631 | 0.190 |
Why?
|
Viremia | 1 | 2024 | 707 | 0.180 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2016 | 3613 | 0.180 |
Why?
|
Interferon-alpha | 1 | 2004 | 921 | 0.170 |
Why?
|
Venous Pressure | 1 | 2019 | 56 | 0.170 |
Why?
|
Phosphorus | 3 | 2011 | 336 | 0.160 |
Why?
|
Ligation | 1 | 2019 | 448 | 0.160 |
Why?
|
Cold Ischemia | 1 | 2018 | 70 | 0.150 |
Why?
|
Glomerular Filtration Rate | 5 | 2018 | 2176 | 0.140 |
Why?
|
HLA-DR Antigens | 1 | 2018 | 602 | 0.130 |
Why?
|
Antibodies | 1 | 2004 | 2418 | 0.130 |
Why?
|
Virus Activation | 1 | 2017 | 322 | 0.120 |
Why?
|
Immunosuppressive Agents | 3 | 2024 | 4174 | 0.120 |
Why?
|
Cytomegalovirus | 1 | 2018 | 756 | 0.120 |
Why?
|
Dexamethasone | 1 | 2021 | 1948 | 0.110 |
Why?
|
Withholding Treatment | 1 | 2017 | 617 | 0.110 |
Why?
|
Liver Transplantation | 1 | 2004 | 2330 | 0.100 |
Why?
|
Cytomegalovirus Infections | 1 | 2018 | 831 | 0.100 |
Why?
|
Middle Aged | 18 | 2024 | 220895 | 0.090 |
Why?
|
Databases, Factual | 3 | 2024 | 7967 | 0.090 |
Why?
|
Male | 22 | 2024 | 360804 | 0.090 |
Why?
|
Pulsatile Flow | 1 | 2011 | 321 | 0.090 |
Why?
|
Antiviral Agents | 2 | 2018 | 3060 | 0.080 |
Why?
|
Recovery of Function | 1 | 2019 | 2979 | 0.080 |
Why?
|
Manometry | 1 | 2011 | 454 | 0.080 |
Why?
|
Antibodies, Monoclonal | 2 | 2021 | 9177 | 0.080 |
Why?
|
Adrenal Cortex Hormones | 1 | 2017 | 1880 | 0.080 |
Why?
|
Humans | 28 | 2024 | 761504 | 0.080 |
Why?
|
Female | 18 | 2024 | 392644 | 0.070 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2011 | 632 | 0.070 |
Why?
|
Myocardial Infarction | 1 | 2009 | 11460 | 0.070 |
Why?
|
Acute Disease | 1 | 2018 | 7237 | 0.070 |
Why?
|
Time Factors | 6 | 2024 | 39967 | 0.070 |
Why?
|
Incidence | 3 | 2020 | 21353 | 0.070 |
Why?
|
Arteries | 1 | 2011 | 1123 | 0.070 |
Why?
|
Kidney Diseases | 1 | 2017 | 2091 | 0.070 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2020 | 4026 | 0.060 |
Why?
|
Complement C4b | 1 | 2005 | 126 | 0.060 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2017 | 4369 | 0.060 |
Why?
|
Hypertension, Renovascular | 1 | 2005 | 116 | 0.060 |
Why?
|
Cyclosporine | 2 | 2004 | 778 | 0.060 |
Why?
|
Adult | 11 | 2024 | 221177 | 0.060 |
Why?
|
Tissue Donors | 2 | 2005 | 2331 | 0.060 |
Why?
|
Renal Artery Obstruction | 1 | 2005 | 219 | 0.060 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2017 | 4580 | 0.050 |
Why?
|
Risk Factors | 6 | 2020 | 74206 | 0.050 |
Why?
|
Antibody Specificity | 1 | 2005 | 1060 | 0.050 |
Why?
|
Mycophenolic Acid | 1 | 2004 | 348 | 0.050 |
Why?
|
Treatment Outcome | 4 | 2024 | 64680 | 0.050 |
Why?
|
Retrospective Studies | 6 | 2024 | 80636 | 0.050 |
Why?
|
Skin Neoplasms | 1 | 2020 | 5821 | 0.050 |
Why?
|
Kidney Function Tests | 2 | 2018 | 678 | 0.050 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2006 | 3810 | 0.050 |
Why?
|
Interferons | 1 | 2004 | 706 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 11742 | 0.040 |
Why?
|
Glomerulonephritis, Membranous | 1 | 2001 | 88 | 0.040 |
Why?
|
Biopsy | 2 | 2018 | 6766 | 0.040 |
Why?
|
Age Factors | 4 | 2011 | 18395 | 0.040 |
Why?
|
Transplantation, Homologous | 2 | 2006 | 4806 | 0.040 |
Why?
|
Steroids | 1 | 2024 | 929 | 0.040 |
Why?
|
Chronic Disease | 2 | 2005 | 9318 | 0.040 |
Why?
|
Aged | 9 | 2024 | 169289 | 0.040 |
Why?
|
Risk Assessment | 3 | 2017 | 23995 | 0.040 |
Why?
|
Thrombosis | 1 | 2012 | 2942 | 0.040 |
Why?
|
Tunica Media | 2 | 2008 | 112 | 0.040 |
Why?
|
New England | 1 | 2020 | 1054 | 0.040 |
Why?
|
Vitamin D | 1 | 2011 | 3303 | 0.040 |
Why?
|
Hepacivirus | 1 | 2004 | 1336 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 4575 | 0.040 |
Why?
|
Child | 2 | 2020 | 80153 | 0.030 |
Why?
|
Adolescent | 2 | 2020 | 88319 | 0.030 |
Why?
|
Tunica Intima | 2 | 2008 | 459 | 0.030 |
Why?
|
Inflammation | 2 | 2012 | 10773 | 0.030 |
Why?
|
Recombinant Fusion Proteins | 1 | 2024 | 3734 | 0.030 |
Why?
|
Hospital Mortality | 1 | 2009 | 5294 | 0.030 |
Why?
|
Coronary Disease | 1 | 2008 | 5914 | 0.030 |
Why?
|
Stents | 1 | 2005 | 3179 | 0.030 |
Why?
|
Clinical Protocols | 1 | 2018 | 1440 | 0.030 |
Why?
|
Peptide Fragments | 1 | 2005 | 5112 | 0.030 |
Why?
|
Acute Kidney Injury | 1 | 2005 | 1924 | 0.030 |
Why?
|
Cross-Sectional Studies | 3 | 2012 | 26125 | 0.030 |
Why?
|
Cause of Death | 1 | 2003 | 3683 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2017 | 1870 | 0.030 |
Why?
|
Cohort Studies | 4 | 2018 | 41487 | 0.020 |
Why?
|
Atherosclerosis | 1 | 2008 | 3408 | 0.020 |
Why?
|
Aged, 80 and over | 2 | 2009 | 58976 | 0.020 |
Why?
|
Compliance | 1 | 2011 | 100 | 0.020 |
Why?
|
Coronary Artery Disease | 1 | 2011 | 6403 | 0.020 |
Why?
|
Prognosis | 3 | 2018 | 29625 | 0.020 |
Why?
|
Georgia | 1 | 2011 | 185 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2018 | 2426 | 0.020 |
Why?
|
Health Surveys | 1 | 2020 | 4061 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2017 | 12059 | 0.020 |
Why?
|
DNA, Viral | 1 | 2017 | 2202 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2024 | 12341 | 0.020 |
Why?
|
Serum Albumin | 1 | 2012 | 672 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2017 | 6228 | 0.020 |
Why?
|
Mississippi | 1 | 2008 | 95 | 0.020 |
Why?
|
Blood Flow Velocity | 1 | 2011 | 1371 | 0.020 |
Why?
|
C-Reactive Protein | 2 | 2012 | 3826 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2017 | 6484 | 0.020 |
Why?
|
Prospective Studies | 3 | 2020 | 54425 | 0.020 |
Why?
|
Lymphocyte Culture Test, Mixed | 1 | 2006 | 509 | 0.020 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 2006 | 364 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2017 | 3156 | 0.020 |
Why?
|
Interleukin-10 | 1 | 2011 | 1175 | 0.020 |
Why?
|
Recurrence | 1 | 2017 | 8465 | 0.020 |
Why?
|
Survival Analysis | 1 | 2017 | 10090 | 0.010 |
Why?
|
Health Personnel | 1 | 2018 | 3335 | 0.010 |
Why?
|
Survival Rate | 1 | 2018 | 12725 | 0.010 |
Why?
|
Macaca fascicularis | 1 | 2006 | 903 | 0.010 |
Why?
|
Lymphocyte Depletion | 1 | 2006 | 602 | 0.010 |
Why?
|
Follow-Up Studies | 2 | 2018 | 39106 | 0.010 |
Why?
|
Lymphocyte Count | 1 | 2006 | 778 | 0.010 |
Why?
|
Transplantation Chimera | 1 | 2006 | 594 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2011 | 36426 | 0.010 |
Why?
|
Hematuria | 1 | 2005 | 233 | 0.010 |
Why?
|
Sex Distribution | 1 | 2008 | 2281 | 0.010 |
Why?
|
Prednisolone | 1 | 2004 | 326 | 0.010 |
Why?
|
Kidney | 1 | 2018 | 7048 | 0.010 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2001 | 5671 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2008 | 2927 | 0.010 |
Why?
|
Vascular Diseases | 1 | 2011 | 1161 | 0.010 |
Why?
|
Cardiovascular Diseases | 2 | 2008 | 15500 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2012 | 3208 | 0.010 |
Why?
|
Child, Preschool | 1 | 2005 | 42230 | 0.010 |
Why?
|
Proteinuria | 1 | 2005 | 607 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2012 | 4352 | 0.010 |
Why?
|
Homocysteine | 1 | 2004 | 638 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 7390 | 0.010 |
Why?
|
Linear Models | 1 | 2011 | 5871 | 0.010 |
Why?
|
Models, Animal | 1 | 2006 | 2112 | 0.010 |
Why?
|
Leukocytes, Mononuclear | 1 | 2006 | 1844 | 0.010 |
Why?
|
Postoperative Period | 1 | 2004 | 1813 | 0.010 |
Why?
|
Angiography | 1 | 2005 | 1595 | 0.010 |
Why?
|
Cholesterol, LDL | 1 | 2008 | 2382 | 0.010 |
Why?
|
Cholesterol | 1 | 2008 | 2904 | 0.010 |
Why?
|
Monitoring, Physiologic | 1 | 2006 | 1779 | 0.010 |
Why?
|
T-Lymphocyte Subsets | 1 | 2006 | 1802 | 0.010 |
Why?
|
Uric Acid | 1 | 2004 | 807 | 0.010 |
Why?
|
Calcium | 1 | 2011 | 5722 | 0.010 |
Why?
|
Immune Tolerance | 1 | 2006 | 2303 | 0.010 |
Why?
|
Nephrotic Syndrome | 1 | 2001 | 390 | 0.010 |
Why?
|
Odds Ratio | 1 | 2008 | 9646 | 0.010 |
Why?
|
Risk | 1 | 2008 | 9610 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2011 | 15266 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2011 | 22176 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2011 | 20098 | 0.010 |
Why?
|
Blood Pressure | 1 | 2004 | 8481 | 0.000 |
Why?
|
Graft vs Host Disease | 1 | 2001 | 3029 | 0.000 |
Why?
|
Hypertension | 1 | 2008 | 8540 | 0.000 |
Why?
|
Disease Progression | 1 | 2005 | 13506 | 0.000 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2008 | 12148 | 0.000 |
Why?
|
United States | 1 | 2011 | 72334 | 0.000 |
Why?
|
Animals | 1 | 2006 | 168459 | 0.000 |
Why?
|